Amicus Therapeutics Inc., of Cranbury, N.J., said the EMA's Committee for Medicinal Products for Human Use granted accelerated assessment to the oral small-molecule pharmacological chaperone migalastat HCL monotherapy for Fabry patients who have amenable genetic mutations.